Skip Ribbon Commands
Skip to main content
Menu

CYTOGENOMIC MICROARRAY ANALYSIS (CMA) TEST: CMA-HAEMATOLOGICAL AND CMA-SOLID TUMOURS

Synonym(s):

​CMA-HAEMATOLOGICAL, CMA-SOLID-TUMOURS

Lab Section Category

Description

Indications

CMA-Haematological test detects both large (whole chromosome) and very small (in exon level) chromosomal gains/losses, at an average revolution of 25 kb for myelodysplastic syndrome (MDS), acute lymphoblastic leukaemia (ALL), acute myeloid leukaemia (AML), and other haematological disorders. In addition, copy number neutral loss of heterozygosity (CN-LOH) which may confer an adverse prognosis to the disease may also be detected. It is recommended for patients with haematological disorders at diagnosis or relapse. It is not suitable for patients following treatment or for monitoring minimal residual disease. 

CMA-Solid Tumours is a standalone CMA tests for solid tumours using FFPE sections. For CMA-Solid Tumours, the overall average resolution is 9Mb and the information of CN-LOH is not able to be obtained.


Specimen Required

CMA-Haematological: collect 2ml bone marrow (2nd aspirate preferred) specimen in a lithium heparinized vacutainer.

CMA-Solid Tumours: 8-10 sections of 5μm FFPE tumour sections, accompanied by a copy of H&E section with the tumour region marked out.

Storage and Transport

​Keep at room temperature and send to the lab on the sampling date, or keep at 4°C and send to the lab on the next day.

Method

​CMA is carried out using the Agilent SurePrint G3 Cancer CGH+SNP (AMADID 030587) 4x180K slide. For CMA-Haematological, the referred sample and reference Agilent Euro Male/Female sample are processed with the Agilent Complete SureTag Enzymatic Labeling kit.

For CMA-Solid Tumours the referred sample and reference control sample are processed using Agilent ULS labelling kit.

Data are analyzed with the Agilent Cytogenomics software version 5.0.2.5 using the default Mosaic Analysis Method.

Test Results

​CMA test results will be reported as normal, abnormal or unavailable (insufficient DNA obtained from samples).


Abnormal CMA results are reported in accordance to the International System for Human Cytogenomic Nomenclature (ISCN, 2020). In addition, reports will include interpretation, comments and references.

Reference Interval / Value

Turnaround Time

​Within 21 days.

Day(s) Test Set up

​Monday – Friday (office hours)

Remarks

Change History Notes

Others

TOP

What's New

Sort by :